Netarsudil and Latanoprost for Glaucoma and Ocular Hypertension
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Recruiting
Phase 4Interventional Study
Ocular HypertensionSuspect Glaucoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
University of Maryland, Baltimore · Other
Who this trial is looking for
This trial is looking for adults with ocular hypertension or suspects of glaucoma. Participants will receive treatment with either latanoprost or Rocklatan and undergo several eye tests before, during, and after treatment.
Are You a Good Fit for This Trial?
You may be able to join if
I am at least 18 years old.
I have ocular hypertension or am a glaucoma suspect.
I have not used any IOP-lowering medications in the past 6 months.
I have open angles in my eyes as shown by a gonioscopy.
I have had a visual field exam within the last 6 months.
You may not be able to join if
I have participated in other investigational studies recently.
I have had prior eye surgery other than cataract surgery.
I am allergic to ICG, shellfish, or iodine.
I have significant liver disease or uremia.
I have secondary glaucoma or a history of acute angle closure.
I have moderate or severe visual field deficits.
I have any condition that prevents reliable imaging.
I am pregnant or nursing.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and lase…
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI).
The main questions this study aims to answer are:
* Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone?
* Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications?
Participants will:
* Be randomized to receive either latanoprost or Rocklatan
* Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and
* Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements.
Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion:
* Patients are at least 18 years of age.
* Patients must have ocular hypertension or be a glaucoma suspect.
* Patient must not have used any IOP-lowering medication (topical or systemic) within the past 6 months
* Patients must have open angles on gonioscopy.
* All patients will have at …
Inclusion:
* Patients are at least 18 years of age.
* Patients must have ocular hypertension or be a glaucoma suspect.
* Patient must not have used any IOP-lowering medication (topical or systemic) within the past 6 months
* Patients must have open angles on gonioscopy.
* All patients will have at least one recorded visual field examination within 6 months of enrollment in the study. Visual fields will be assessed using the Hodapp-Andersen-Parish criteria.
Exclusion:
* Participation in other investigational studies, unless such participation does not involve the administration of any drugs or agents that could impact the results of this study or have an effect on episcleral flow, as determined by the Investigator.
* Prior intraocular surgery other than uncomplicated cataract surgery.
* Allergy or history of adverse reaction to ICG, shellfish, or Iodine.
* Significant liver disease or uremia.
* Secondary glaucoma including exfoliation glaucoma, pigmentary glaucoma, or history of acute angle closure.
* Moderate or severe visual field deficits as per Hodapp-Anderson-Parish criteria.
* Any condition precluding imaging including reliable visual fields, disc photography, or use of study treatments including media opacity or tilted optic disk
* Pregnant or nursing patients.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
